Jiangsu Hengrui Pharmaceuticals (SHA:600276, HKG:1276) obtained approval for two new indications of its Hetrombopag Olamine Tablets from China's National Medical Products Administration.
The first indication is for the treatment of adult patients with thrombocytopenia caused by chemotherapy-based anti-tumor therapy for solid tumors, according to a Thursday bourse filing.
The other indication is for pediatric patients over six years of age with chronic primary immune thrombocytopenia.